# Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

> **NCT01888562** · NA · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Endometrial Neoplasms

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT01888562
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2018-07
- **Final completion:** 2023-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Could not obtain an IDE on the FGFR2 assay
- **Last updated:** 2015-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888562, "Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01888562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*